https://www.pharmaradar360.com/article/glass-pumpkin-patch-at-the-arboretum-d02dfdd728c01c10PharmaRadar360en2026-09-18T16:48:06.000ZGlass Pumpkin Patch at the Arboretumhttps://www.pharmaradar360.com/article/when-ev-dose-is-not-what-it-seems-quantitative-mismatch-between-particle-number-f47a7c5a1a3284b4PharmaRadar360en2026-09-18T16:29:38.000ZWhen EV Dose Is Not What It Seems: Quantitative Mismatch Between Particle Number- and Protein-Based Dosinghttps://www.pharmaradar360.com/article/semi-mechanistic-joint-population-pharmacokinetic-modeling-of-the-novel-antitube-ebec18c2810c96c6PharmaRadar360en2026-09-18T16:02:31.000ZSemi-Mechanistic Joint Population Pharmacokinetic Modeling of the Novel Antituberculosis Drug Sorfequiline and Its Metabolite M3 in Healthy Volunteershttps://www.pharmaradar360.com/article/biotech-options-buzz-uthr-nmra-ewtx-904141373556fd38PharmaRadar360en2026-09-18T15:46:04.000ZBiotech Options Buzz: UTHR, NMRA, EWTXhttps://www.pharmaradar360.com/article/do-you-have-to-be-bilingual-to-participate-in-circle-u-activities-c8b706a758c482a8PharmaRadar360en2026-09-18T15:39:27.000ZDo you have to be bilingual to participate in Circle U. activitieshttps://www.pharmaradar360.com/article/definium-trial-suggests-lsd-could-help-treat-anxiety-one-patient-meets-god-the-o-cb4c52a47721d100PharmaRadar360en2026-09-18T15:30:35.000ZDefinium trial suggests LSD could help treat anxiety; “One patient meets God. The other gets itchy.”; and Compass funds psilocybin-assisted therapist traininghttps://www.pharmaradar360.com/article/emirates-biotech-and-partner-launch-uae-organic-waste-to-biogas-pilot-7528d116c86d5b63PharmaRadar360en2026-09-18T15:24:56.000ZEmirates Biotech and partner launch UAE organic waste-to-biogas pilothttps://www.pharmaradar360.com/article/how-circle-u-helped-me-define-my-career-path-81b7d487eea3e910PharmaRadar360en2026-09-18T15:21:13.000ZHow Circle U. helped me define my career pathhttps://www.pharmaradar360.com/article/xenon-stock-craters-30-on-drug-trial-setback-its-failure-could-be-this-biotech-s-56a2fa84d3bb02c3PharmaRadar360en2026-09-18T15:12:00.000ZXenon Stock Craters 30% on Drug Trial Setback. Its Failure Could Be This Biotech’s Gain.https://www.pharmaradar360.com/article/frazier-life-sciences-adds-1-1b-to-biotech-fund-84639908b0e2b140PharmaRadar360en2026-09-18T15:06:05.000ZFrazier Life Sciences Adds $1.1B to Biotech Fundhttps://www.pharmaradar360.com/article/novartis-receives-positive-chmp-opinion-for-cosentyx-in-polymyalgia-rheumatica-p-72f0f6aa86cf0f0bPharmaRadar360en2026-09-18T15:04:43.000ZNovartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)https://www.pharmaradar360.com/article/a-20-anos-sin-lopez-se-renueva-el-reclamo-por-verdad-y-justicia-4b7984b231467d6ePharmaRadar360en2026-09-18T15:02:26.000ZA 20 años sin López, se renueva el reclamo por verdad y justiciahttps://www.pharmaradar360.com/article/european-adrs-slip-in-us-trading-as-biotech-splits-5d79b846c95a7a75PharmaRadar360en2026-09-18T15:00:13.000ZEuropean ADRs Slip In US Trading As Biotech Splitshttps://www.pharmaradar360.com/article/37-000-ai-agents-are-running-a-virtual-biotech-at-stanford-486a0da87125e24aPharmaRadar360en2026-09-18T14:52:51.000Z37,000 AI Agents Are Running a Virtual Biotech at Stanfordhttps://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-nasdaq-rare-sees-large-volume-increase-after-analyst-u-02e90aaa7ef82c7cPharmaRadar360en2026-09-18T14:42:34.000ZUltragenyx Pharmaceutical (NASDAQ:RARE) Sees Large Volume Increase After Analyst Upgradehttps://www.pharmaradar360.com/article/how-rebate-timing-distorts-a-pharmacy-s-340b-books-3fc20171d90a422cPharmaRadar360en2026-09-18T14:41:40.000ZHow Rebate Timing Distorts a Pharmacy's 340B Bookshttps://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-nasdaq-rare-price-target-raised-to-32-00-e4b617ea41d02a41PharmaRadar360en2026-09-18T14:38:33.000ZUltragenyx Pharmaceutical (NASDAQ:RARE) Price Target Raised to $32.00https://www.pharmaradar360.com/article/guidance-covid-19-test-validation-approved-products-8740f36d3b2718d0PharmaRadar360en2026-09-18T14:38:10.000ZGuidance: COVID-19 test validation approved productshttps://www.pharmaradar360.com/article/biotech-catalyst-stocks-with-binary-events-coming-up-0e77c7de51362b23PharmaRadar360en2026-09-18T14:36:13.000ZBiotech catalyst stocks with binary events coming uphttps://www.pharmaradar360.com/article/spn-exclusive-an-early-look-at-mcc-s-completed-3-million-biotech-lab-68ba636d342ac5cfPharmaRadar360en2026-09-18T14:30:00.000ZSPN Exclusive: An early look at MCC’s completed $3 million biotech labhttps://www.pharmaradar360.com/article/fda-approves-first-gene-therapy-for-sanfilippo-syndrome-type-a-ddacc8fe3f2a7e07PharmaRadar360en2026-09-18T14:26:15.000ZFDA approves first gene therapy for Sanfilippo syndrome type Ahttps://www.pharmaradar360.com/article/q-a-how-can-sponsors-respond-to-clinical-trial-customs-delays-6f1b84efeb049467PharmaRadar360en2026-09-18T14:24:16.000ZQ&A: How Can Sponsors Respond to Clinical Trial Customs Delays?https://www.pharmaradar360.com/article/ufrj-debate-defesa-da-democracia-confrontos-e-estrategias-de-comunicacao-em-reun-9eb7532f7d41d72aPharmaRadar360en2026-09-18T14:23:57.000ZUFRJ debate defesa da democracia, confrontos e estratégias de comunicação em reunião com professores eméritoshttps://www.pharmaradar360.com/article/fda-hearing-psychedelics-launch-needs-balanced-regulation-without-limiting-acces-81cc63fd87c8c2d5PharmaRadar360en2026-09-18T14:22:40.000ZFDA hearing: psychedelics launch needs balanced regulation without limiting accesshttps://www.pharmaradar360.com/article/fierce-pharma-asia-china-deals-safe-from-coins-key-wclc-data-legend-s-new-ceo-c23fdc3b607774daPharmaRadar360en2026-09-18T14:20:52.000ZFierce Pharma Asia—China deals safe from COINS?; Key WCLC data; Legend’s new CEOhttps://www.pharmaradar360.com/article/introducing-the-pharmtech-ai-pulse-check-expert-video-series-c9a61784abb684dePharmaRadar360en2026-09-18T14:20:07.000ZIntroducing the "PharmTech AI Pulse Check" Expert Video Serieshttps://www.pharmaradar360.com/article/nordic-perspectives-on-education-a-two-book-launch-335960b186ef8c7dPharmaRadar360en2026-09-18T14:06:32.000ZNordic Perspectives on Education: A Two-Book Launchhttps://www.pharmaradar360.com/article/virtual-biotech-ai-system-advances-drug-discovery-with-37-000-agents-6df6d3ca1fbffbc8PharmaRadar360en2026-09-18T14:01:42.000ZVirtual Biotech AI System Advances Drug Discovery with 37,000 Agentshttps://www.pharmaradar360.com/article/a-closer-look-at-the-50-billion-rural-health-transformation-program-76a13771919bcee8PharmaRadar360en2026-09-18T14:00:00.000ZA Closer Look at the $50 Billion Rural Health Transformation Programhttps://www.pharmaradar360.com/article/bucks-county-biotech-hub-and-doylestown-hospital-land-state-grants-for-new-proje-8665c163a0e7a8bcPharmaRadar360en2026-09-18T14:00:00.000ZBucks County Biotech Hub and Doylestown Hospital Land State Grants for New Projectshttps://www.pharmaradar360.com/article/novo-targets-oral-macrocycles-with-1-4bn-orbis-partnership-6671ed6a26e6a1c2PharmaRadar360en2026-09-18T13:52:30.000ZNovo targets oral macrocycles with $1.4bn Orbis partnershiphttps://www.pharmaradar360.com/article/what-is-drawing-fresh-attention-to-takeda-pharmaceutical-tse-4502-8ed4853f5f8b35ebPharmaRadar360en2026-09-18T13:44:21.000ZWhat Is Drawing Fresh Attention To Takeda Pharmaceutical (TSE:4502)?https://www.pharmaradar360.com/article/roche-expands-its-boston-footprint-with-new-research-center-61c8eaa9d2c59da9PharmaRadar360en2026-09-18T13:43:52.000ZRoche expands its Boston footprint with new research centerhttps://www.pharmaradar360.com/article/inside-the-growing-world-of-biopharma-prediction-markets-765a66b0e486f7ccPharmaRadar360en2026-09-18T13:39:41.000ZInside the growing world of biopharma prediction marketshttps://www.pharmaradar360.com/article/veradermics-buy-before-the-catalysts-nyse-mane-5202da45b7aa63c8PharmaRadar360en2026-09-18T13:39:00.000ZVeradermics: Buy Before The Catalysts (NYSE:MANE)https://www.pharmaradar360.com/article/shingles-can-cause-severe-chronic-pain-new-research-on-how-exosomes-alter-neuron-2a6301bdbff0f775PharmaRadar360en2026-09-18T13:33:48.000ZShingles Can Cause Severe Chronic Pain – New Research On How Exosomes Alter Neurons Offers Pathways To Treatmenthttps://www.pharmaradar360.com/article/4-westchester-fairfield-leaders-advocate-for-health-and-raise-funds-critical-for-78121da21d239558PharmaRadar360en2026-09-18T13:29:00.000Z4 Westchester/Fairfield leaders advocate for health and raise funds critical for fighting heart diseasehttps://www.pharmaradar360.com/article/seqens-brings-its-personal-care-and-custom-specialties-activities-together-withi-48e0fd6157eea57ePharmaRadar360en2026-09-18T13:27:31.000ZSEQENS brings its Personal Care and Custom & Specialties activities together within a single organization.https://www.pharmaradar360.com/article/reasons-to-add-west-pharmaceutical-stock-to-your-portfolio-now-a987741149fa9bd2PharmaRadar360en2026-09-18T13:21:00.000ZReasons to Add West Pharmaceutical Stock to Your Portfolio Nowhttps://www.pharmaradar360.com/article/why-this-biotech-just-nearly-erased-its-one-day-50-pop-69c3a9008e5f3dadPharmaRadar360en2026-09-18T13:15:00.000ZWhy This Biotech Just Nearly Erased Its One-Day 50% Pophttps://www.pharmaradar360.com/article/aces-alumna-employs-biotech-to-create-sustainable-livestock-production-bcccea6733969c2cPharmaRadar360en2026-09-18T13:12:17.000ZACES alumna employs biotech to create sustainable livestock productionhttps://www.pharmaradar360.com/article/stanford-virtual-biotech-links-target-expression-patterns-to-higher-drug-success-4f2cc92095f808d2PharmaRadar360en2026-09-18T13:04:57.000ZStanford Virtual Biotech links target expression patterns to higher drug successhttps://www.pharmaradar360.com/article/state-fiscal-conditions-context-on-medicaid-budgets-for-fy-2027-a4d0ffddaeb7db7dPharmaRadar360en2026-09-18T13:00:00.000ZState Fiscal Conditions: Context on Medicaid Budgets for FY 2027https://www.pharmaradar360.com/article/chutes-ladders-legend-poaches-novartis-vet-to-boost-commercial-potential-e80965543b112e35PharmaRadar360en2026-09-18T12:53:06.000ZChutes & Ladders—Legend poaches Novartis vet to boost commercial potentialhttps://www.pharmaradar360.com/article/auszeichnungen-fur-herausragende-forschung-und-innovation-in-der-infektiologie-2e2b4d68c515c033PharmaRadar360en2026-09-18T12:46:20.000ZAuszeichnungen für herausragende Forschung und Innovation in der Infektiologiehttps://www.pharmaradar360.com/article/canaccord-genuity-group-increases-ultragenyx-pharmaceutical-nasdaq-rare-price-ta-7cfbe3170174b2c9PharmaRadar360en2026-09-18T12:45:11.000ZCanaccord Genuity Group Increases Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $39.00https://www.pharmaradar360.com/article/west-pharma-to-cut-98-jobs-as-smartdose-production-winds-down-in-arizona-47ebb0bb9de0baddPharmaRadar360en2026-09-18T12:35:00.000ZWest Pharma to cut 98 jobs as SmartDose production winds down in Arizonahttps://www.pharmaradar360.com/article/unc-global-affairs-encourages-more-study-abroad-in-japan-b882c10bbd673b89PharmaRadar360en2026-09-18T12:34:51.000ZUNC Global Affairs encourages more study abroad in Japanhttps://www.pharmaradar360.com/article/scientists-discover-cells-that-cheat-death-and-rebuild-damaged-tissue-2ba232951401badcPharmaRadar360en2026-09-18T12:30:43.000ZScientists discover cells that cheat death and rebuild damaged tissuehttps://www.pharmaradar360.com/article/abbvie-highlights-new-real-world-data-supporting-the-effectiveness-of-vraylar-ca-4c1f376b38b218c5PharmaRadar360en2026-09-18T12:30:00.000ZAbbVie Highlights New Real-World Data Supporting the Effectiveness of VRAYLAR® (cariprazine) at Psych Congress 2026https://www.pharmaradar360.com/article/lakewood-amedex-starts-phase-2a-trial-for-nu-3-to-treat-diabetic-foot-ulcers-wit-e4b94f11fe4c68f0PharmaRadar360en2026-09-18T12:24:15.000ZLakewood-Amedex starts Phase 2a trial for Nu-3 to treat diabetic foot ulcers with drug-resistant infectionshttps://www.pharmaradar360.com/article/jahresbericht-des-krebsregisters-der-kantone-zurich-zug-schaffhausen-und-schwyz-63636ce70813c644PharmaRadar360en2026-09-18T12:14:30.000ZJahresbericht des Krebsregisters der Kantone Zürich, Zug, Schaffhausen und Schwyzhttps://www.pharmaradar360.com/article/cantor-fitzgerald-forecasts-strong-price-appreciation-for-ultragenyx-pharmaceuti-a94686663212042bPharmaRadar360en2026-09-18T12:13:08.000ZCantor Fitzgerald Forecasts Strong Price Appreciation for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stockhttps://www.pharmaradar360.com/article/a-new-gel-for-infected-diabetic-foot-ulcers-is-ready-for-a-clinical-trial-9baca5ba6094011dPharmaRadar360en2026-09-18T12:13:00.000ZA new gel for infected diabetic foot ulcers is ready for a clinical trialhttps://www.pharmaradar360.com/article/lakewood-amedex-biotherapeutics-announces-irb-approval-and-clinical-site-readine-6c633ac91c89ca34PharmaRadar360en2026-09-18T12:13:00.000ZLakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcershttps://www.pharmaradar360.com/article/ligand-pharmaceuticals-owning-it-gives-you-a-stake-across-biotech-nasdaq-lgnd-a5490902b4f252f8PharmaRadar360en2026-09-18T12:06:16.000ZLigand Pharmaceuticals: Owning It Gives You A Stake Across Biotech (NASDAQ:LGND)https://www.pharmaradar360.com/article/countering-motor-neuron-degeneration-with-base-editing-155eca28b20c8601PharmaRadar360en2026-09-18T12:00:00.000ZCountering Motor Neuron Degeneration with Base Editinghttps://www.pharmaradar360.com/article/establishment-of-two-new-on-site-laboratories-approved-465c999c4a9c1229PharmaRadar360en2026-09-18T12:00:00.000ZEstablishment of two new On-site Laboratories approvedhttps://www.pharmaradar360.com/article/signatm-artist-and-signatm-artist-evo-b43f2d2ea4307776PharmaRadar360en2026-09-18T12:00:00.000ZSIGNA™ Artist and SIGNA™ Artist Evohttps://www.pharmaradar360.com/article/pune-fda-seizes-adulterated-food-worth-rs-56-36-lakh-banned-gutkha-worth-rs-20-2-b25b754ddcb9cba2PharmaRadar360en2026-09-18T11:38:22.000ZPune FDA Seizes Adulterated Food Worth Rs 56.36 Lakh, Banned Gutkha Worth Rs 20.26 Lakh in Festive Drivehttps://www.pharmaradar360.com/article/ukri-space-lab-hosts-first-uk-pm-and-head-of-nato-meeting-484a0b72310be070PharmaRadar360en2026-09-18T11:33:37.000ZUKRI Space Lab hosts first UK PM and Head of NATO meetinghttps://www.pharmaradar360.com/article/abeona-therapeutics-congratulates-ultragenyx-on-u-s-fda-approval-of-fayuvitm-gen-08da3da710ebe595PharmaRadar360en2026-09-18T11:30:00.000ZAbeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)https://www.pharmaradar360.com/article/das-universitatsklinikum-heidelberg-ist-grundungsmitglied-von-medi-cus-bff2845ac3e34d06PharmaRadar360en2026-09-18T11:29:44.000ZDas Universitätsklinikum Heidelberg ist Gründungsmitglied von MEDI:CUShttps://www.pharmaradar360.com/article/suny-funding-to-advance-tech-that-could-improve-patient-care-9e34ce94de8cee0fPharmaRadar360en2026-09-18T11:22:11.000ZSUNY funding to advance tech that could improve patient carehttps://www.pharmaradar360.com/article/china-unveils-a-new-five-year-plan-for-developing-pharmaceutical-industry-44919095069d11e6PharmaRadar360en2026-09-18T11:14:00.000ZChina unveils a new five-year plan for developing pharmaceutical industryhttps://www.pharmaradar360.com/article/why-executive-mfn-deals-aren-t-enough-q-a-with-joe-cunningham-48c869a29e6c3e7fPharmaRadar360en2026-09-18T11:10:17.000ZWhy Executive MFN Deals Aren't Enough: Q&A with Joe Cunninghamhttps://www.pharmaradar360.com/article/addressing-mfn-innovation-concerns-568aea26781afe55PharmaRadar360en2026-09-18T11:10:17.000ZAddressing MFN Innovation Concernshttps://www.pharmaradar360.com/article/can-ai-agents-satisfy-cgmp-documentation-requirements-609a4915047af303PharmaRadar360en2026-09-18T11:04:14.000ZCan AI Agents Satisfy CGMP Documentation Requirements?https://www.pharmaradar360.com/article/shining-a-light-on-uterine-cancer-rising-incidence-and-mortality-persistent-ineq-b6df0ffb13807c1dPharmaRadar360en2026-09-18T11:00:17.000ZShining a Light on Uterine Cancer: Rising Incidence and Mortality, Persistent Inequitieshttps://www.pharmaradar360.com/article/bristol-myers-squibb-to-report-results-for-third-quarter-2026-on-october-29-2026-915d65a4fe2302cbPharmaRadar360en2026-09-18T10:59:00.000ZBristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026https://www.pharmaradar360.com/article/exclusive-us-weighs-allowing-most-pharma-licensing-deals-with-china-sources-say-d48516f28aaf5220PharmaRadar360en2026-09-18T10:56:40.000ZEXCLUSIVE: US weighs allowing most pharma licensing deals with China, sources sayhttps://www.pharmaradar360.com/article/exclusive-us-weighs-allowing-most-pharma-licensing-deals-with-china-sources-say-9eef7f5883b17b66PharmaRadar360en2026-09-18T10:55:03.000ZExclusive-US weighs allowing most pharma licensing deals with China, sources sayhttps://www.pharmaradar360.com/article/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumab-plus-padcev-e-9dda3e8e04d1e9eaPharmaRadar360en2026-09-18T10:55:00.000ZMerck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)https://www.pharmaradar360.com/article/chmp-recommends-eu-approval-of-roche-s-ocrevus-for-children-and-adolescents-with-7987b36e70396aa4PharmaRadar360en2026-09-18T10:45:00.000ZCHMP recommends EU approval of Roche’s Ocrevus for children and adolescents with relapsing multiple sclerosishttps://www.pharmaradar360.com/article/merck-launches-your-hive-of-whole-health-to-support-whole-person-care-for-people-6fb49d94bbe3b4f2PharmaRadar360en2026-09-18T10:45:00.000ZMerck Launches Your Hive of Whole Health to Support Whole Person Care for People Living With HIVhttps://www.pharmaradar360.com/article/china-targets-3-5-trillion-yuan-pharmaceutical-industry-by-2030-ea3e6220b6b84bbfPharmaRadar360en2026-09-18T10:37:00.000ZChina Targets 3.5 Trillion Yuan Pharmaceutical Industry by 2030https://www.pharmaradar360.com/article/a-sellas-immunotherapy-study-long-delayed-will-end-in-failure-4f39356374c8bccbPharmaRadar360en2026-09-18T10:28:36.000ZA Sellas immunotherapy study, long delayed, will end in failurehttps://www.pharmaradar360.com/article/investors-pour-over-30b-into-longevity-biotech-companies-8159bc55d8a873cePharmaRadar360en2026-09-18T10:15:47.000ZInvestors pour over $30B into longevity biotech companieshttps://www.pharmaradar360.com/article/nuvectis-pharma-haisco-licensing-deal-revitalises-biotech-but-no-rush-to-invest-9e5025881f0236a4PharmaRadar360en2026-09-18T10:15:05.000ZNuvectis Pharma:Haisco Licensing Deal Revitalises Biotech, But No Rush To Invest Now(NVCT)https://www.pharmaradar360.com/article/chicago-biotech-inomagen-lands-up-to-2-9m-for-gene-therapy-targeting-afib-2314e0a3b1c7a48dPharmaRadar360en2026-09-18T10:15:00.000ZChicago biotech Inomagen lands up to $2.9M for gene therapy targeting AFibhttps://www.pharmaradar360.com/article/investors-pour-over-30b-into-longevity-biotech-companies-fe16e000e0bbdcc4PharmaRadar360en2026-09-18T10:13:53.000ZInvestors pour over $30B into longevity biotech companieshttps://www.pharmaradar360.com/article/market-movers-rx-west-pharmaceutical-services-leads-gainers-d11ab73a9d464311PharmaRadar360en2026-09-18T10:10:17.000ZMarket Movers RX: West Pharmaceutical Services Leads Gainershttps://www.pharmaradar360.com/article/understanding-the-latest-with-mfn-pricing-and-what-it-means-to-pharma-611640f35e9de0d0PharmaRadar360en2026-09-18T10:10:17.000ZUnderstanding the Latest with MFN Pricing and What It Means to Pharmahttps://www.pharmaradar360.com/article/novartis-india-acquires-pfizer-s-minipress-brands-for-150-million-717f175a2a74699dPharmaRadar360en2026-09-18T10:04:35.000ZNovartis India acquires Pfizer’s Minipress brands for $150 millionhttps://www.pharmaradar360.com/article/alterity-therapeutics-nasdaq-athe-to-outline-msa-drug-plans-at-asx-smidcaps-conf-1fca461c030238b6PharmaRadar360en2026-09-18T10:03:29.000ZAlterity Therapeutics (NASDAQ: ATHE) to outline MSA drug plans at ASX SMIDcaps conferencehttps://www.pharmaradar360.com/article/xenon-pauses-phase-3-depression-trials-after-psychosis-events-c474442598d818f4PharmaRadar360en2026-09-18T10:03:00.000ZXenon pauses phase 3 depression trials after psychosis eventshttps://www.pharmaradar360.com/article/clear-labels-act-stripped-of-key-provisions-before-senate-vote-81d6841a7d217e7cPharmaRadar360en2026-09-18T10:00:00.000ZCLEAR LABELS Act stripped of key provisions before Senate votehttps://www.pharmaradar360.com/article/a-clear-watering-down-drug-transparency-bill-stripped-of-critical-provisions-ahe-5a903264c20ac795PharmaRadar360en2026-09-18T10:00:00.000Z“A Clear Watering Down”: Drug Transparency Bill Stripped of Critical Provisions Ahead of Senate Votehttps://www.pharmaradar360.com/article/the-key-to-success-is-being-willing-to-understand-the-energy-system-9887c5050e48720dPharmaRadar360en2026-09-18T09:57:06.000Z‘The key to success is being willing to understand the energy system’https://www.pharmaradar360.com/article/these-blood-thinners-may-have-an-unexpected-benefit-for-alzheimer-s-patients-daa8fc27301148bfPharmaRadar360en2026-09-18T09:48:31.000ZThese blood thinners may have an unexpected benefit for Alzheimer’s patientshttps://www.pharmaradar360.com/article/cantor-fitzgerald-maintains-overweight-rating-on-ultragenyx-pharmaceutical-39-pr-90bfb8ef4162d81ePharmaRadar360en2026-09-18T09:41:18.000ZCantor Fitzgerald maintains Overweight rating on Ultragenyx Pharmaceutical, $39 price targethttps://www.pharmaradar360.com/article/novo-bets-on-ai-designed-macrocycles-in-orbis-oral-drugs-deal-3d2fb0a79abc2e12PharmaRadar360en2026-09-18T09:28:45.000ZNovo bets on AI-designed macrocycles in Orbis oral drugs dealhttps://www.pharmaradar360.com/article/grunenthal-prices-850m-euros-of-notes-to-refinance-and-fund-expansion-51639ee1c0a91b88PharmaRadar360en2026-09-18T09:24:14.000ZGrünenthal prices 850m euros of notes to refinance and fund expansionhttps://www.pharmaradar360.com/article/rapport-therapeutics-inc-rapp-stock-analysis-a-clinical-stage-biotech-with-a-49-bb04e31254be6de9PharmaRadar360en2026-09-18T09:19:49.000ZRapport Therapeutics, Inc. (RAPP) Stock Analysis: A Clinical-Stage Biotech with a 49.90% Upside Potentialhttps://www.pharmaradar360.com/article/celcuity-inc-celc-stock-analysis-unpacking-an-89-32-potential-upside-in-biotech-ed1c905c6f09d8a1PharmaRadar360en2026-09-18T09:19:25.000ZCelcuity Inc. (CELC) Stock Analysis: Unpacking An 89.32% Potential Upside In Biotechhttps://www.pharmaradar360.com/article/oruka-therapeutics-inc-orka-stock-analysis-a-58-6-potential-upside-beckons-biote-d636f4afe1bf33f2PharmaRadar360en2026-09-18T09:19:23.000ZOruka Therapeutics, Inc. (ORKA) Stock Analysis: A 58.6% Potential Upside Beckons Biotech Investorshttps://www.pharmaradar360.com/article/oric-pharmaceuticals-oric-stock-analysis-a-60-upside-potential-with-strong-buy-r-8623ff2cd166514bPharmaRadar360en2026-09-18T09:19:20.000ZOric Pharmaceuticals (ORIC) Stock Analysis: A 60% Upside Potential with Strong Buy Ratings in Biotechhttps://www.pharmaradar360.com/article/primo-capital-launches-biotech-venture-fund-for-italy-s-lazio-region-b6ff7a9c7111e9f9PharmaRadar360en2026-09-18T09:09:55.000ZPrimo Capital launches biotech venture fund for Italy's Lazio regionhttps://www.pharmaradar360.com/article/a-journey-to-self-discovery-the-story-of-a-circle-u-student-fellow-5fea8b858725c8aePharmaRadar360en2026-09-18T09:06:34.000ZA journey to self discovery – the story of a Circle U. Student Fellowhttps://www.pharmaradar360.com/article/the-drugs-and-devices-have-been-on-the-market-for-years-but-fda-ordered-studies-f50b3d6ed1b0bc0dPharmaRadar360en2026-09-18T09:03:49.000ZThe Drugs and Devices Have Been on the Market for Years. But FDA-Ordered Studies Still Aren’t Done.https://www.pharmaradar360.com/article/the-specter-of-ai-enabled-bioweapons-is-a-wake-up-call-for-biotech-f0e619b6ad1a6523PharmaRadar360en2026-09-18T09:00:00.000ZThe specter of AI-enabled bioweapons is a wake-up call for biotechhttps://www.pharmaradar360.com/article/decision-marketing-authorisations-granted-in-2026-0fc9c2c1015a12a7PharmaRadar360en2026-09-18T08:52:31.000ZDecision: Marketing authorisations Granted in 2026https://www.pharmaradar360.com/article/decision-parallel-import-licences-granted-in-2026-f337a3e18a403d26PharmaRadar360en2026-09-18T08:52:27.000ZDecision: Parallel import licences granted in 2026https://www.pharmaradar360.com/article/lb-pharmaceuticals-rated-buy-with-85-base-value-150-potential-if-phase-3-succeed-9332fe094c538a69PharmaRadar360en2026-09-18T08:46:20.000ZLB Pharmaceuticals rated buy with $85 base value, $150 potential if Phase 3 succeeds by 2027https://www.pharmaradar360.com/article/mhra-consultation-on-statutory-fees-2026-4e7ecd381fcc9a03PharmaRadar360en2026-09-18T08:45:02.000ZMHRA consultation on statutory fees (2026)https://www.pharmaradar360.com/article/biotech-stocks-at-52-week-highs-mnov-36-pbls-10-abcl-9-hae-neo-140ed34b93773a97PharmaRadar360en2026-09-18T08:36:00.000ZBiotech Stocks At 52-Week Highs - MNOV +36%, PBLS +10%, ABCL +9%, HAE, NEOhttps://www.pharmaradar360.com/article/boehringer-discontinues-phase-iii-easi-kidney-trial-of-vicadrostat-5d694399009054c9PharmaRadar360en2026-09-18T08:35:26.000ZBoehringer discontinues Phase III EASi-KIDNEY trial of vicadrostathttps://www.pharmaradar360.com/article/dimerix-asx-dxb-action3-kidney-disease-trial-remains-central-to-development-path-aa84609d9f537b5bPharmaRadar360en2026-09-18T08:34:00.000ZDimerix (ASX:DXB): ACTION3 Kidney Disease Trial Remains Central to Development Pathhttps://www.pharmaradar360.com/article/hexavalent-combination-vaccine-programme-guidance-83f6b178f952c923PharmaRadar360en2026-09-18T08:30:02.000ZHexavalent combination vaccine: programme guidancehttps://www.pharmaradar360.com/article/0366002724-ur-test-120ml-sterile-108d430e0a4ba326PharmaRadar360en2026-09-18T08:14:32.000ZΑνάκληση της παρτίδας 0366002724 του Ιατροτεχνολογικού προϊόντος UR-TEST 120ml Sterile Ουροσυλλέκτηςhttps://www.pharmaradar360.com/article/vendanges-sur-le-site-hospitalier-des-hus-de-la-robertsau-pour-les-residents-de-c010efcb07425afdPharmaRadar360en2026-09-18T08:13:19.000ZVendanges sur le site hospitalier des HUS de la Robertsau pour les résidents de l’EHPAD : héritage patrimonial et lien intergénérationnelhttps://www.pharmaradar360.com/article/a-guide-to-sarms-definition-side-effects-and-dangers-e67630b4d57afdc1PharmaRadar360en2026-09-18T08:00:59.000ZA Guide to SARMs: Definition, Side Effects, and Dangershttps://www.pharmaradar360.com/article/biomedicine-powerhouse-china-targets-quarter-of-global-first-in-class-drugs-6b7e17dcbf9db5c6PharmaRadar360en2026-09-18T08:00:06.000ZBiomedicine powerhouse: China targets quarter of global first-in-class drugshttps://www.pharmaradar360.com/article/herzmedizin-und-anatomie-beim-festival-der-wissenschaft-und-neugier-ae5897933fcd4fa9PharmaRadar360en2026-09-18T07:42:16.000ZHerzmedizin und Anatomie beim „Festival der Wissenschaft und Neugier“https://www.pharmaradar360.com/article/bms-dumps-100m-orum-degrader-antibody-conjugate-after-glimpsing-phase-1-data-24ceb75fbe9947cePharmaRadar360en2026-09-18T07:41:37.000ZBMS dumps $100M Orum degrader-antibody conjugate after glimpsing phase 1 datahttps://www.pharmaradar360.com/article/trump-administration-shift-puts-this-corner-of-biotech-back-in-favor-9c761ffe135492bbPharmaRadar360en2026-09-18T07:28:36.000ZTrump Administration Shift Puts This Corner of Biotech Back in Favorhttps://www.pharmaradar360.com/article/why-i-keep-going-back-to-ukraine-during-wartime-df612d9b073be5dcPharmaRadar360en2026-09-18T07:26:33.000ZWhy I keep going back to Ukraine during wartimehttps://www.pharmaradar360.com/article/millimeterarbeit-gegen-lungentumoren-die-music-studie-53be2a6ee6a105b4PharmaRadar360en2026-09-18T07:14:56.000ZMillimeterarbeit gegen Lungentumoren: die MUSIC-Studiehttps://www.pharmaradar360.com/article/pawbio-animal-health-biologics-services-1a048e6660565241PharmaRadar360en2026-09-18T07:13:03.000ZPawBio Animal Health Biologics Serviceshttps://www.pharmaradar360.com/article/tumore-al-seno-in-humanitas-torna-paziente-diplomata-e54455d5d56e61c1PharmaRadar360en2026-09-18T07:03:41.000ZTumore al seno: in Humanitas torna “Paziente diplomata”https://www.pharmaradar360.com/article/chronisch-entzundliche-darmerkrankungen-im-fokus-a1687f02fff393f7PharmaRadar360en2026-09-18T07:03:18.000ZChronisch-entzündliche Darmerkrankungen im Fokushttps://www.pharmaradar360.com/article/unmc-brings-ems-professionals-to-omaha-for-training-4f1f1a30c9c75fcbPharmaRadar360en2026-09-18T07:00:00.000ZUNMC brings EMS professionals to Omaha for traininghttps://www.pharmaradar360.com/article/insilico-medicine-s-alex-zhavoronkov-bets-china-and-ai-can-deliver-the-drug-indu-bf58fc441aef28acPharmaRadar360en2026-09-18T07:00:00.000ZInsilico Medicine's Alex Zhavoronkov bets China and AI can deliver the drug industry’s next breakthroughhttps://www.pharmaradar360.com/article/anna-maria-fjordb-ge-discussed-ethnographic-findings-on-digitalisation-and-judic-741ca0d3539fbc98PharmaRadar360en2026-09-18T06:58:57.000ZAnna Maria Fjordbøge discussed ethnographic findings on digitalisation and judicial independencehttps://www.pharmaradar360.com/article/inflammation-biotech-electra-charges-up-with-350m-from-upsized-ipo-58f7ac98a3c81cd2PharmaRadar360en2026-09-18T06:58:51.000ZInflammation biotech Electra charges up with $350M from upsized IPOhttps://www.pharmaradar360.com/article/candidate-christy-knorr-tours-unmc-9c858ca4e9103a33PharmaRadar360en2026-09-18T06:58:00.000ZCandidate Christy Knorr tours UNMChttps://www.pharmaradar360.com/article/employee-giving-campaign-runs-through-sept-25-3d755fdad3d90840PharmaRadar360en2026-09-18T06:56:00.000ZEmployee Giving Campaign runs through Sept. 25https://www.pharmaradar360.com/article/dr-klepser-to-lead-session-on-culture-by-design-673f758cb628666cPharmaRadar360en2026-09-18T06:54:00.000ZDr. Klepser to lead session on ‘Culture by Design’https://www.pharmaradar360.com/article/unmc-for-the-record-sept-18-2026-26f128b25ad022fcPharmaRadar360en2026-09-18T06:50:00.000ZUNMC for the record, Sept. 18, 2026https://www.pharmaradar360.com/article/aspen-leader-shares-insights-on-advancing-healthcare-transformation-across-afric-e197406ab7edc88cPharmaRadar360en2026-09-18T06:40:19.000ZAspen leader shares insights on advancing healthcare transformation across Africahttps://www.pharmaradar360.com/article/foundationone-cdx-alk-9df8eafd03eb3fdaPharmaRadar360en2026-09-18T06:30:00.000ZFoundationOne CDx がんゲノムプロファイル、ALK融合遺伝子陽性の非小細胞肺癌に対するロルラチニブのコンパニオン診断として承認を取得https://www.pharmaradar360.com/article/chugai-obtains-approval-for-foundationone-cdx-cancer-genomic-profile-as-a-compan-a1b0d45f052647e4PharmaRadar360en2026-09-18T06:30:00.000ZChugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic of Lorlatinib for ALK Fusion Gene-Positive Non-Small Cell Lung Cancerhttps://www.pharmaradar360.com/article/otsuka-and-jolly-good-launch-new-content-for-faceduo-dementia-care-support-vr-un-2392b089dce1c64fPharmaRadar360en2026-09-18T06:00:00.000ZOtsuka and Jolly Good Launch New Content for FACEDUO Dementia Care Support VR Understanding a New Perspective on Dementiahttps://www.pharmaradar360.com/article/fete-de-la-science-2026-b279a061dcc65a5cPharmaRadar360en2026-09-18T06:00:00.000ZFête de la science 2026https://www.pharmaradar360.com/article/tissue-repair-asx-trp-phase-3-wound-healing-trial-remains-central-to-development-7287d50919577414PharmaRadar360en2026-09-18T05:55:00.000ZTissue Repair (ASX:TRP): Phase 3 Wound Healing Trial Remains Central to Development Pathhttps://www.pharmaradar360.com/article/china-unveils-15th-five-year-plan-for-pharmaceutical-industry-targeting-over-20-2ab6174a22012261PharmaRadar360en2026-09-18T05:55:00.000ZChina Unveils 15th Five-Year Plan for Pharmaceutical Industry, Targeting Over 20% Annual Revenue Growth in Innovative Drugshttps://www.pharmaradar360.com/article/flu-vaccination-in-the-social-care-sector-63cb5603bb33eecdPharmaRadar360en2026-09-18T05:45:14.000ZFlu vaccination in the social care sectorhttps://www.pharmaradar360.com/article/the-latest-iphone-apple-watch-and-airpods-lineups-arrive-in-stores-worldwide-ec905d3774ad7d98PharmaRadar360en2026-09-18T05:02:14.000ZThe latest iPhone, Apple Watch, and AirPods lineups arrive in stores worldwidehttps://www.pharmaradar360.com/article/etra-ipo-news-antibody-biotech-electra-therapeutics-prices-upsized-ipo-at-15-mid-bd92cafd24c85550PharmaRadar360en2026-09-18T04:59:00.000ZETRA IPO News - Antibody biotech Electra Therapeutics prices upsized IPO at $15 midpointhttps://www.pharmaradar360.com/article/2026-7-10-15-943b204f7d94498aPharmaRadar360en2026-09-18T04:57:29.000Z2026年度 第7回東北大学病院がんセミナー開催のお知らせ（10/15開催）https://www.pharmaradar360.com/article/slv-revenue-fell-14-and-net-loss-widened-as-biotech-demand-dropped-but-drug-deve-44b2d4b9fcc80835PharmaRadar360en2026-09-18T04:55:00.000ZSLV: Revenue fell 14% and net loss widened as biotech demand dropped, but Drug Development grew 16%https://www.pharmaradar360.com/article/ultragenyx-shares-rise-after-hours-following-fda-approval-ultragenyx-pharmaceuti-4517cfdb85b67294PharmaRadar360en2026-09-18T04:26:40.000ZUltragenyx Shares Rise After Hours Following FDA Approval - Ultragenyx Pharmaceutical (NASDAQ:RARE)https://www.pharmaradar360.com/article/scientists-restore-a-brain-protein-and-reverse-signs-of-aging-in-mice-e17168fca74ee1f1PharmaRadar360en2026-09-18T04:25:45.000ZScientists restore a brain protein and reverse signs of aging in micehttps://www.pharmaradar360.com/article/characteristics-of-low-voltage-zones-in-patients-with-heart-failure-with-preserv-5bb4200b0c0df75ePharmaRadar360en2026-09-18T04:03:44.000ZCharacteristics of Low‐Voltage Zones in Patients With Heart Failure With Preserved Ejection Fractionhttps://www.pharmaradar360.com/article/nitric-oxide-delivery-system-correction-noxbox-updates-use-instructions-for-noxb-a4f02b1fa9701d35PharmaRadar360en2026-09-18T04:00:00.000ZNitric Oxide Delivery System Correction: NOxBOX Updates Use Instructions for NOxBOXi Nitric Oxide Delivery Systemhttps://www.pharmaradar360.com/article/ozempic-can-change-your-body-can-it-change-your-life-d702a2323ab8162ePharmaRadar360en2026-09-18T03:52:09.000ZOzempic can change your body. Can it change your life?https://www.pharmaradar360.com/article/dr-reddy-s-labs-agrees-to-licensing-deal-with-gilead-for-once-yearly-lenacapavir-c6e21fe407ab9575PharmaRadar360en2026-09-18T03:38:34.000ZDr. Reddy's Labs Agrees To Licensing Deal With Gilead For Once-Yearly Lenacapavir To Prevent HIVhttps://www.pharmaradar360.com/article/mumbai-s-olympia-coffee-house-where-christopher-nolan-stopped-for-chai-loses-lic-bb4065e6955e1adcPharmaRadar360en2026-09-18T03:35:10.000ZMumbai's Olympia Coffee House, where Christopher Nolan stopped for chai, loses licencehttps://www.pharmaradar360.com/article/food-safety-crackdown-fda-suspends-licences-of-seven-mumbai-establishments-1bc5a4018c01d902PharmaRadar360en2026-09-18T03:11:00.000ZFood safety crackdown: FDA suspends licences of seven Mumbai establishmentshttps://www.pharmaradar360.com/article/innate-pharma-ipha-q2-2026-earnings-call-transcript-2453cef2f5f167e5PharmaRadar360en2026-09-18T03:07:53.000ZInnate Pharma (IPHA) Q2 2026 Earnings Call Transcripthttps://www.pharmaradar360.com/article/51cc077bbc6c89d0PharmaRadar360en2026-09-18T03:01:15.000Z上部尿路（腎盂・尿管）がん術後の膀胱内再発予防に ピラルビシン膀注療法が有効であることを証明https://www.pharmaradar360.com/article/shinsa-samd-page-updated-guide-revised-seminar-videos-and-materials-published-co-619e30c9b864d6f8PharmaRadar360en2026-09-18T03:00:00.000Z[SHINSA]SaMD page updated (guide revised, seminar videos and materials published, consultation schedule updated)https://www.pharmaradar360.com/article/fda-suspends-cafe-mondegar-licence-over-food-safety-lapses-wider-crackdown-hits-dbf096ce62824842PharmaRadar360en2026-09-18T02:46:03.000ZFDA suspends Café Mondegar licence over food-safety lapses; wider crackdown hits Mumbai eaterieshttps://www.pharmaradar360.com/article/montana-s-new-rules-let-licensed-clinics-sell-drugs-that-cleared-only-phase-1-sa-9e447bd6f824af4ePharmaRadar360en2026-09-18T02:14:49.000ZMontana's New Rules Let Licensed Clinics Sell Drugs That Cleared Only Phase 1 Safety Testing to Paying Patientshttps://www.pharmaradar360.com/article/feb-19-2026-dhl-group-expands-airfreight-cold-chain-network-to-advance-global-he-b4b7754991d65e96PharmaRadar360en2026-09-18T02:08:32.000ZFeb 19, 2026: DHL Group expands Airfreight Cold Chain Network to advance global health logisticshttps://www.pharmaradar360.com/article/etfs-investing-in-shaanxi-panlong-pharmaceutical-group-co-ltd-class-a-stocks-474793fb82a908a6PharmaRadar360en2026-09-18T02:01:50.000ZETFs Investing in Shaanxi Panlong Pharmaceutical Group Co., Ltd. Class A Stockshttps://www.pharmaradar360.com/article/passaparola-21-09-120-anni-della-clinica-mangiagalli-celebriamo-la-culla-d-itali-3c6d6707f48c60b7PharmaRadar360en2026-09-18T02:00:00.000Z#PASSAPAROLA [21.09] 120 anni della Clinica Mangiagalli: celebriamo la culla d’Italiahttps://www.pharmaradar360.com/article/is-ultragenyx-pharmaceutical-rare-reasonable-after-its-fda-gene-therapy-approval-92ee3504e9cb0a80PharmaRadar360en2026-09-18T01:48:34.000ZIs Ultragenyx Pharmaceutical (RARE) Reasonable After Its FDA Gene Therapy Approval?https://www.pharmaradar360.com/article/bombay-high-court-asks-thane-restaurant-to-approach-food-safety-commissioner-ove-cb94d91d3cc4472dPharmaRadar360en2026-09-18T01:43:46.000ZBombay High Court asks Thane restaurant to approach Food Safety Commissioner over licence suspensionhttps://www.pharmaradar360.com/article/simulations-plus-expands-fda-adoption-of-admet-predictor-with-new-licenses-for-t-e883165e7f599585PharmaRadar360en2026-09-18T01:26:35.000ZSimulations Plus Expands FDA Adoption of ADMET Predictor® with New Licenses for the Cosmetics Regulatory Science Branchhttps://www.pharmaradar360.com/article/electra-amasses-350m-in-biotech-s-latest-big-ipo-978099deecfc2361PharmaRadar360en2026-09-18T01:16:16.000ZElectra amasses $350M in biotech’s latest big IPOhttps://www.pharmaradar360.com/article/exclusive-astrazeneca-s-new-breast-cancer-drug-etracama-to-enter-korea-4a59ef93e0c56fb3PharmaRadar360en2026-09-18T00:50:46.000Z[Exclusive] AstraZeneca's New Breast Cancer Drug Etracama to Enter Koreahttps://www.pharmaradar360.com/article/12-tucsco-10-6-c99883a9f629ce01PharmaRadar360en2026-09-18T00:43:04.000Z第12回 東北大学ケアサイエンス共創センター（TUCSCO）セミナー開催のお知らせ（10/6開催）https://www.pharmaradar360.com/article/electra-s-350m-ipo-will-help-it-become-a-commercial-biotech-64654e6782d6b4d8PharmaRadar360en2026-09-18T00:43:00.000ZElectra’s $350M IPO will help it become a commercial biotechhttps://www.pharmaradar360.com/article/electra-therapeutics-announces-pricing-of-upsized-350-0-million-initial-public-o-5224881caefa3cfaPharmaRadar360en2026-09-18T00:30:00.000ZElectra Therapeutics Announces Pricing of Upsized $350.0 Million Initial Public Offeringhttps://www.pharmaradar360.com/article/area-biotech-looks-ahead-7f2eaf55a0c8b74aPharmaRadar360en2026-09-18T00:19:00.000ZArea biotech looks aheadhttps://www.pharmaradar360.com/article/exclusive-retail-investors-buy-68-3b-won-in-sejong-medical-c5ee1465e913cc8fPharmaRadar360en2026-09-18T00:14:45.000ZExclusive: Retail Investors Buy 68.3B Won in Sejong Medicalhttps://www.pharmaradar360.com/article/astrazeneca-filed-form-6-k-dd6239a9df91643dPharmaRadar360en2026-09-18T00:00:00.000ZAstraZeneca filed Form 6-Khttps://www.pharmaradar360.com/article/a-universal-visual-foundation-model-for-computational-cytopathology-d4d82831813740f5PharmaRadar360en2026-09-18T00:00:00.000ZA universal visual foundation model for computational cytopathologyhttps://www.pharmaradar360.com/article/serotonin-neurons-in-the-dorsal-raphe-control-food-craving-like-behavior-during-9b1cc1d30ce78bfdPharmaRadar360en2026-09-18T00:00:00.000ZSerotonin neurons in the dorsal raphe control food-craving-like behavior during pregnancy in micehttps://www.pharmaradar360.com/article/reciprocal-connections-dynamically-build-consensus-between-neocortical-areas-2904d1c3185e72a1PharmaRadar360en2026-09-18T00:00:00.000ZReciprocal connections dynamically build consensus between neocortical areashttps://www.pharmaradar360.com/article/two-parallel-neural-ectoderm-progenitors-contribute-to-the-developing-brain-27601ed7284656ccPharmaRadar360en2026-09-18T00:00:00.000ZTwo parallel neural ectoderm progenitors contribute to the developing brainhttps://www.pharmaradar360.com/article/editorial-expression-of-concern-swi-snf-mutant-cancers-depend-on-catalytic-and-n-fa22820503a0bb23PharmaRadar360en2026-09-18T00:00:00.000ZEditorial Expression of Concern: SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2https://www.pharmaradar360.com/article/how-genes-shape-personality-and-experience-8e6ff560799a1d26PharmaRadar360en2026-09-18T00:00:00.000ZHow genes shape personality and experiencehttps://www.pharmaradar360.com/article/chinese-companies-doubled-down-on-science-after-us-tech-restrictions-f5dc675196375a6ePharmaRadar360en2026-09-18T00:00:00.000ZChinese companies doubled down on science after US tech restrictionshttps://www.pharmaradar360.com/article/first-for-rna-therapy-man-with-rare-motor-neuron-disease-improves-after-treatmen-39d5d7d56656617aPharmaRadar360en2026-09-18T00:00:00.000ZFirst for RNA therapy: man with rare motor-neuron disease improves after treatmenthttps://www.pharmaradar360.com/article/europe-pushes-for-space-independence-amid-geopolitical-rifts-2bcc4551592c59fcPharmaRadar360en2026-09-18T00:00:00.000ZEurope pushes for space independence amid geopolitical riftshttps://www.pharmaradar360.com/article/cognitive-resilience-helps-to-predict-alzheimer-s-dementia-61ec2e4b02e7618bPharmaRadar360en2026-09-18T00:00:00.000ZCognitive resilience helps to predict Alzheimer’s dementiahttps://www.pharmaradar360.com/article/how-research-funding-took-me-out-of-the-lab-and-into-leadership-b04ee2454e589d00PharmaRadar360en2026-09-18T00:00:00.000ZHow research funding took me out of the lab and into leadershiphttps://www.pharmaradar360.com/article/first-myostatin-targeted-antibody-approved-for-spinal-muscular-atrophy-2956859569b7854dPharmaRadar360en2026-09-18T00:00:00.000ZFirst myostatin-targeted antibody approved for spinal muscular atrophyhttps://www.pharmaradar360.com/article/the-value-of-speed-for-drug-developers-1de79cdc9775c318PharmaRadar360en2026-09-18T00:00:00.000ZThe value of speed for drug developershttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-99468576d4475ecdPharmaRadar360en2026-09-18T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9794-4-crore-consolidated-revenue-and-e2-82-b9206-5-crore-o-0cd044981af5ad1fPharmaRadar360en2026-09-18T00:00:00.000Znatco records %e2%82%b9794 4 crore consolidated revenue and %e2%82%b9206 5 crore of profit after tax for q1 fy27https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-8dd79c3a6f6e87edPharmaRadar360en2026-09-18T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-62516a983397efc4PharmaRadar360en2026-09-18T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-37d5d8d5c2c18251PharmaRadar360en2026-09-18T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-24ca4672ffc8689dPharmaRadar360en2026-09-18T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-2c167272dd414ca5PharmaRadar360en2026-09-18T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-01f8759d83e0ece0PharmaRadar360en2026-09-18T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-limited-announces-conclusion-of-us-fda-inspection-at-visakhapatnam-3c0ef826ba0e428bPharmaRadar360en2026-09-18T00:00:00.000Znatco pharma limited announces conclusion of us fda inspection at visakhapatnam andhra pradesh finished dosage formulations fdf unithttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-089df69bf082a363PharmaRadar360en2026-09-18T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-26a72c8773f961bfPharmaRadar360en2026-09-18T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-30139f173ab191c4PharmaRadar360en2026-09-18T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/investment-of-us-14-million-in-egenesis-inc-by-natco-pharma-canada-inc-and-natco-4daed0de11c9d6a0PharmaRadar360en2026-09-18T00:00:00.000Zinvestment of us 14 million in egenesis inc by natco pharma canada inc and natco pharma south africa proprietary limitedhttps://www.pharmaradar360.com/article/home-page-626670b9461fce6dPharmaRadar360en2026-09-18T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/national-vaccine-injury-compensation-program-list-of-petitions-received-6091ed1340d56d14PharmaRadar360en2026-09-18T00:00:00.000ZNational Vaccine Injury Compensation Program; List of Petitions Receivedhttps://www.pharmaradar360.com/article/electronic-submission-template-for-medical-device-premarket-approval-application-84868d5f9c7d515fPharmaRadar360en2026-09-18T00:00:00.000ZElectronic Submission Template for Medical Device Premarket Approval Applications (PMAs); Draft Guidance for Industry and Food and Drug Administration Staff; Availabilityhttps://www.pharmaradar360.com/article/agency-forms-undergoing-paperwork-reduction-act-review-604ead149a445115PharmaRadar360en2026-09-18T00:00:00.000ZAgency Forms Undergoing Paperwork Reduction Act Reviewhttps://www.pharmaradar360.com/article/biosimilar-user-fee-act-iii-future-needs-in-the-development-of-interchangeable-p-fe5a68d526ec88a9PharmaRadar360en2026-09-18T00:00:00.000ZBiosimilar User Fee Act III Future Needs in the Development of Interchangeable Products Post-Workshop; Draft Strategy Documenthttps://www.pharmaradar360.com/article/national-institute-of-allergy-and-infectious-diseases-amended-notice-of-meeting-dcb583623cf5f6f4PharmaRadar360en2026-09-18T00:00:00.000ZNational Institute of Allergy and Infectious Diseases; Amended Notice of Meetinghttps://www.pharmaradar360.com/article/proposed-collection-60-day-comment-request-post-award-reporting-requirements-inc-48f728e96892f8f4PharmaRadar360en2026-09-18T00:00:00.000ZProposed Collection; 60-Day Comment Request; Post-Award Reporting Requirements Including Research Performance Progress Report (OD)https://www.pharmaradar360.com/article/proposed-collection-60-day-comment-request-phs-applications-and-pre-award-report-45801451bb9edd47PharmaRadar360en2026-09-18T00:00:00.000ZProposed Collection; 60-Day Comment Request; PHS Applications and Pre-Award Reporting Requirements (OD)https://www.pharmaradar360.com/article/notice-of-supplemental-funding-delta-region-community-health-systems-development-8a467900dbe269e1PharmaRadar360en2026-09-18T00:00:00.000ZNotice of Supplemental Funding, Delta Region Community Health Systems Development Programhttps://www.pharmaradar360.com/article/healthy-start-self-measured-blood-pressure-monitoring-9a807fe7b2052867PharmaRadar360en2026-09-18T00:00:00.000ZHealthy Start Self-Measured Blood Pressure Monitoringhttps://www.pharmaradar360.com/article/infant-toddler-court-program-national-resource-center-87bdf4a836c3d8dbPharmaRadar360en2026-09-18T00:00:00.000ZInfant-Toddler Court Program-National Resource Centerhttps://www.pharmaradar360.com/article/target-animal-safety-evaluation-for-veterinary-monoclonal-antibody-products-draf-c6d6364c139b35dePharmaRadar360en2026-09-18T00:00:00.000ZTarget Animal Safety Evaluation for Veterinary Monoclonal Antibody Products; Draft Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/national-library-of-medicine-notice-of-partially-closed-meeting-4cae51d99da667c3PharmaRadar360en2026-09-18T00:00:00.000ZNational Library of Medicine; Notice of Partially Closed Meetinghttps://www.pharmaradar360.com/article/center-for-scientific-review-amended-notice-of-meeting-3df8df59fcecf4b6PharmaRadar360en2026-09-18T00:00:00.000ZCenter for Scientific Review; Amended Notice of Meetinghttps://www.pharmaradar360.com/article/national-center-for-advancing-translational-sciences-amended-notice-of-meeting-ce1fbb114382a049PharmaRadar360en2026-09-18T00:00:00.000ZNational Center for Advancing Translational Sciences; Amended Notice of Meetinghttps://www.pharmaradar360.com/article/notice-of-supplemental-funding-national-rural-health-policy-community-and-collab-d1edde2289a9483fPharmaRadar360en2026-09-18T00:00:00.000ZNotice of Supplemental Funding, National Rural Health Policy, Community, and Collaboration Programhttps://www.pharmaradar360.com/article/notice-of-supplemental-funding-national-rural-health-information-clearinghouse-p-80273b101abb5b18PharmaRadar360en2026-09-18T00:00:00.000ZNotice of Supplemental Funding, National Rural Health Information Clearinghouse Programhttps://www.pharmaradar360.com/article/notice-of-supplemental-funding-rural-residency-planning-and-development-technica-bad78a3fbc8146b7PharmaRadar360en2026-09-18T00:00:00.000ZNotice of Supplemental Funding; Rural Residency Planning and Development Technical Assistance Programhttps://www.pharmaradar360.com/article/vill-forbattra-varden-vid-kronisk-njursjukdom-da50b1e1d961632cPharmaRadar360en2026-09-18T00:00:00.000ZVill förbättra vården vid kronisk njursjukdomhttps://www.pharmaradar360.com/article/han-breddar-sin-traumaforskning-med-stod-fran-forskar-at-48a89c1bf1f7d034PharmaRadar360en2026-09-18T00:00:00.000ZHan breddar sin traumaforskning med stöd från forskar-AThttps://www.pharmaradar360.com/article/erc-utmarkelse-for-allmanhetens-engagemang-kring-beroring-och-kittlighet-ad92c23fe3cf202fPharmaRadar360en2026-09-18T00:00:00.000ZERC-utmärkelse för allmänhetens engagemang kring beröring och kittlighethttps://www.pharmaradar360.com/article/cascade-watch-a-quality-improvement-approach-to-identifying-and-mitigating-presc-5e4c9b87f73175cePharmaRadar360en2026-09-18T00:00:00.000ZCascade-Watch: A quality improvement approach to identifying and mitigating prescribing cascades in long-term carehttps://www.pharmaradar360.com/article/pharmacists-perspectives-on-generative-artificial-intelligence-tools-in-pharmacy-9364bf8b6a1b9432PharmaRadar360en2026-09-18T00:00:00.000ZPharmacists’ perspectives on generative artificial intelligence tools in pharmacy practice and pharmacy educationhttps://www.pharmaradar360.com/article/pill-splitting-for-sustainability-reducing-the-cost-and-environmental-impact-of-e1421773d0d87402PharmaRadar360en2026-09-18T00:00:00.000ZPill splitting for sustainability: Reducing the cost and environmental impact of medicationshttps://www.pharmaradar360.com/article/practice-tips-for-successful-point-of-care-testing-programs-in-pharmacies-a53ecfbdb2e94510PharmaRadar360en2026-09-18T00:00:00.000ZPractice tips for successful point-of-care testing programs in pharmacieshttps://www.pharmaradar360.com/article/integrating-artificial-intelligence-across-the-cancer-drug-discovery-pipeline-us-d7efd9830701ac32PharmaRadar360en2026-09-18T00:00:00.000ZIntegrating artificial intelligence across the cancer drug discovery pipeline using a design-test-refine workflowhttps://www.pharmaradar360.com/article/pharmaco-multiomics-in-major-depressive-disorder-a-narrative-review-and-proposed-42e75faf60364346PharmaRadar360en2026-09-18T00:00:00.000ZPharmaco-multiomics in major depressive disorder: a narrative review and proposed translational framework for difficult-to-treat and treatment-resistant depressionhttps://www.pharmaradar360.com/article/factors-associated-with-clinical-research-participation-among-medicare-beneficia-b7de054f5c62fdebPharmaRadar360en2026-09-18T00:00:00.000ZFactors associated with clinical research participation among Medicare beneficiaries with prostate cancer in the United Stateshttps://www.pharmaradar360.com/article/from-benchmarking-to-global-leadership-singapore-s-health-sciences-authority-s-j-c9dff2d33578c9ddPharmaRadar360en2026-09-18T00:00:00.000ZFrom benchmarking to global leadership: Singapore’s health sciences authority’s journey to WHO maturity level 4 and WHO-Listed Authority status for medicineshttps://www.pharmaradar360.com/article/a-narrative-review-of-emerging-chemoprotective-agents-for-chemotherapy-induced-t-0a67f03191c1e550PharmaRadar360en2026-09-18T00:00:00.000ZA narrative review of emerging chemoprotective agents for chemotherapy-induced toxicity: nanoformulated natural products, dual COX-2/TNF-α inhibitors, and Nrf2 modulatorshttps://www.pharmaradar360.com/article/the-clinical-trial-landscape-of-bispecific-antibodies-in-non-small-cell-lung-can-bcb034023b34aa44PharmaRadar360en2026-09-18T00:00:00.000ZThe clinical trial landscape of bispecific antibodies in non-small cell lung cancer: mechanistic trends and developmental strategieshttps://www.pharmaradar360.com/article/a-systems-microbiology-framework-for-reproducible-multi-dataset-omics-integratio-b779bce51648b197PharmaRadar360en2026-09-18T00:00:00.000ZA systems microbiology framework for reproducible multi-dataset omics integration with application to long COVIDhttps://www.pharmaradar360.com/article/exploring-traditional-chinese-medicine-to-enhance-the-efficacy-and-reduce-toxici-f47001b561f23943PharmaRadar360en2026-09-18T00:00:00.000ZExploring traditional Chinese medicine to enhance the efficacy and reduce toxicity of immunotherapy for non-small cell lung cancer from the perspective of “spleen deficiency”: a trial protocol for mechanism and clinical evidencehttps://www.pharmaradar360.com/article/bibliometric-and-clinical-trial-landscape-of-hepatoblastoma-2000-2024-a-multi-da-82994bbd094b43d4PharmaRadar360en2026-09-18T00:00:00.000ZBibliometric and clinical trial landscape of hepatoblastoma (2000–2024): a multi-database analysis of global researchhttps://www.pharmaradar360.com/article/method-development-validation-and-estimation-of-single-synthetic-drug-tafamidis-6c0d9c088549a9f2PharmaRadar360en2026-09-18T00:00:00.000ZMethod Development, Validation and Estimation of Single Synthetic Drug Tafamidis by RP-HPLC and Green Analysis in API Form and Pharmaceutical Dosage Formhttps://www.pharmaradar360.com/article/clinical-and-patient-reported-outcomes-in-non-english-speaking-patients-undergoi-ac4dc44140853a67PharmaRadar360en2026-09-18T00:00:00.000ZClinical and Patient-Reported Outcomes in Non-English-Speaking Patients Undergoing Primary Total Knee Arthroplastyhttps://www.pharmaradar360.com/article/bacteriological-quality-of-pharmaceutical-effluents-in-awka-nigeria-37de73039abf6f90PharmaRadar360en2026-09-18T00:00:00.000ZBacteriological Quality of Pharmaceutical Effluents in Awka, Nigeriahttps://www.pharmaradar360.com/article/effectiveness-and-safety-of-screening-colonoscopy-in-adults-aged-75-years-and-ol-6d12f15e1391ea8cPharmaRadar360en2026-09-18T00:00:00.000ZEffectiveness and safety of screening colonoscopy in adults aged 75 years and older: a retrospective cohort study from Koreahttps://www.pharmaradar360.com/article/the-role-of-curcumin-in-neurogenesis-and-neuroprotection-in-alzheimer-s-disease-4243af857122205aPharmaRadar360en2026-09-18T00:00:00.000ZThe Role of Curcumin in Neurogenesis and Neuroprotection in Alzheimer’s disease: From Molecular Mechanisms to Clinical Evidencehttps://www.pharmaradar360.com/article/opioid-management-for-the-primary-care-physician-a-practical-guideline-based-cli-170f2da712920c3fPharmaRadar360en2026-09-18T00:00:00.000ZOpioid Management for the Primary Care Physician: A Practical, Guideline-Based Clinical Reviewhttps://www.pharmaradar360.com/article/nanocarriers-for-targeted-drug-delivery-in-cancer-therapy-innovations-and-challe-1c2dc318af7f590fPharmaRadar360en2026-09-18T00:00:00.000ZNanocarriers for Targeted Drug Delivery in Cancer Therapy: Innovations and Challengeshttps://www.pharmaradar360.com/article/dual-attention-ensemble-residual-learning-for-robust-diabetic-retinopathy-classi-633f8b4a39b678e6PharmaRadar360en2026-09-18T00:00:00.000ZDual-Attention Ensemble Residual Learning for Robust Diabetic Retinopathy Classification under Class Imbalancehttps://www.pharmaradar360.com/article/hand-function-and-oral-hygiene-performance-among-children-with-down-syndrome-a-c-ede1867ad511fb59PharmaRadar360en2026-09-18T00:00:00.000ZHand Function and Oral Hygiene Performance among Children with Down Syndrome: A Cross-Sectional Studyhttps://www.pharmaradar360.com/article/dynamics-and-structure-of-criminal-offenses-related-to-illicit-drug-trafficking-27b75901169137cfPharmaRadar360en2026-09-18T00:00:00.000ZDynamics and structure of criminal offenses related to illicit drug trafficking: legal analysis for Kazakhstanhttps://www.pharmaradar360.com/article/applying-the-american-school-counselor-association-asca-ethical-and-legal-standa-8dcb561e1a538c12PharmaRadar360en2026-09-18T00:00:00.000ZApplying the American School Counselor Association (ASCA) Ethical and Legal Standards to Your Clinical Experienceshttps://www.pharmaradar360.com/article/impact-of-cardiopulmonary-bypass-duration-on-intensive-care-and-hospital-length-15f8968488fed16dPharmaRadar360en2026-09-18T00:00:00.000ZImpact of Cardiopulmonary Bypass Duration on Intensive Care and Hospital Length of Stay in Coronary Artery Bypass Graftinghttps://www.pharmaradar360.com/article/the-effect-of-retrograde-autologous-priming-on-hematocrit-trajectory-and-transfu-5d9c48524efc7152PharmaRadar360en2026-09-18T00:00:00.000ZThe Effect of Retrograde Autologous Priming on Hematocrit Trajectory and Transfusion Requirement in Isolated Coronary Artery Bypass Surgeryhttps://www.pharmaradar360.com/article/aquagenic-palmoplantar-keratoderma-clinical-histopathological-and-ultrastructura-f28fff81510d6c3bPharmaRadar360en2026-09-18T00:00:00.000ZAquagenic palmoplantar keratoderma: Clinical, histopathological, and ultrastructural features in a 54-year-old manhttps://www.pharmaradar360.com/article/combination-therapy-of-biologic-and-non-biologic-systemic-agents-in-psoriasis-a-eb16a4d585839d3aPharmaRadar360en2026-09-18T00:00:00.000ZCombination therapy of biologic and non-biologic systemic agents in psoriasis: A narrative review of real-world evidence and clinical positioninghttps://www.pharmaradar360.com/article/the-neurological-burden-of-cirrhosis-a-comprehensive-clinical-review-of-mechanis-387c5cf15a238ed8PharmaRadar360en2026-09-18T00:00:00.000ZThe neurological burden of cirrhosis: a comprehensive clinical review of mechanisms, diagnosis, and managementhttps://www.pharmaradar360.com/article/xinshuaifang-improves-oxidative-stress-injury-and-myocardial-remodeling-in-acute-ea34efe2d9af33f7PharmaRadar360en2026-09-18T00:00:00.000ZXinshuaifang improves oxidative stress injury and myocardial remodeling in acute heart failure: Association with the gut-heart axishttps://www.pharmaradar360.com/article/dencichine-ameliorates-hepatic-fibrosis-by-modulating-the-pi3k-akt-signaling-pat-1feafa88df28df14PharmaRadar360en2026-09-18T00:00:00.000ZDencichine ameliorates hepatic fibrosis by modulating the PI3K/AKT signaling pathway in cellular and murine modelshttps://www.pharmaradar360.com/article/bmscs-promote-apoptosis-in-glioma-cells-by-inhibiting-stat3-phosphorylation-b0ab18bf9d391818PharmaRadar360en2026-09-18T00:00:00.000ZBMSCs promote apoptosis in glioma cells by inhibiting STAT3 phosphorylationhttps://www.pharmaradar360.com/article/case-report-clinical-and-magnetic-resonance-imaging-findings-in-intracranial-hem-0c206b485101e9e9PharmaRadar360en2026-09-18T00:00:00.000ZCase Report: Clinical and magnetic resonance imaging findings in intracranial hemangiosarcoma in a cathttps://www.pharmaradar360.com/article/artificial-intelligence-for-sleep-disordered-breathing-a-taxonomy-of-methods-dat-4212fb2e9998d4f0PharmaRadar360en2026-09-18T00:00:00.000ZArtificial intelligence for sleep-disordered breathing: a taxonomy of methods, data modalities, and clinical applicationshttps://www.pharmaradar360.com/article/appropriateness-of-antibiotic-prescribing-in-dental-practice-results-of-two-clin-9e717dd8a6e0113dPharmaRadar360en2026-09-18T00:00:00.000ZAppropriateness of antibiotic prescribing in dental practice: results of two clinical audits conducted at a university hospitalhttps://www.pharmaradar360.com/article/exploring-the-effects-of-digital-literacy-training-on-college-students-self-lead-bc9eb38a15681b18PharmaRadar360en2026-09-18T00:00:00.000ZExploring the effects of digital literacy training on college students’ self-leadership: a longitudinal randomized controlled trialhttps://www.pharmaradar360.com/article/mechanism-aware-and-safety-validated-ai-for-drug-repurposing-a-critical-review-a-fe666815e2b4145aPharmaRadar360en2026-09-18T00:00:00.000ZMechanism-aware and safety-validated AI for drug repurposing: a critical review and translational pharmacology frameworkhttps://www.pharmaradar360.com/article/temporal-and-clinical-heterogeneity-of-double-m-protein-multiple-myeloma-diagnos-c674cc6b45f5fa7fPharmaRadar360en2026-09-18T00:00:00.000ZTemporal and clinical heterogeneity of double M-protein multiple myeloma: diagnostic and treatment-emergent phenotypeshttps://www.pharmaradar360.com/article/managing-skin-related-adverse-events-during-mirdametinib-treatment-for-nf1-pns-e-9244fb4fa5c44f88PharmaRadar360en2026-09-18T00:00:00.000ZManaging skin-related adverse events during mirdametinib treatment for NF1-PNs: expert guidance from the ReNeu trialhttps://www.pharmaradar360.com/article/the-clinical-landscape-of-bladder-cancer-treatment-a-brief-report-on-new-develop-2a53d6280762f04bPharmaRadar360en2026-09-18T00:00:00.000ZThe clinical landscape of bladder cancer treatment: a brief report on new developments and future perspectives in pharmaceutical interventionshttps://www.pharmaradar360.com/article/effect-of-antenatal-breast-milk-expression-or-postnatal-dietary-intervention-on-8cf881177dc218d1PharmaRadar360en2026-09-18T00:00:00.000ZEffect of antenatal breast milk expression or postnatal dietary intervention on breastfeeding outcomes and human milk composition in women with excess weight: protocol for the Ready, Set, Nourish study, a randomized controlled trialhttps://www.pharmaradar360.com/article/study-protocol-for-a-randomized-controlled-trial-comparing-penetrating-needling-1ca63ddbb2ae5d59PharmaRadar360en2026-09-18T00:00:00.000ZStudy protocol for a randomized controlled trial comparing penetrating needling and cognitive behavioral therapy for subjective tinnitushttps://www.pharmaradar360.com/article/sacituzumab-govitecan-in-metastatic-breast-cancer-a-systematic-review-and-meta-a-9e64e28209a31e7bPharmaRadar360en2026-09-18T00:00:00.000ZSacituzumab govitecan in metastatic breast cancer: a systematic review and meta-analysis of its clinical benefit and safetyhttps://www.pharmaradar360.com/article/spatial-multi-omics-guided-drug-development-in-inflammatory-bowel-disease-from-m-9d2a193694c20310PharmaRadar360en2026-09-18T00:00:00.000ZSpatial multi-omics-guided drug development in inflammatory bowel disease: from mucosal immune niches to precision therapyhttps://www.pharmaradar360.com/article/multidimensional-efficacy-characterization-of-xeligekimab-in-moderate-to-severe-54a1dbdb991fe995PharmaRadar360en2026-09-18T00:00:00.000ZMultidimensional efficacy characterization of xeligekimab in moderate-to-severe plaque psoriasis: regional responses, treatment targets, and patient-reported outcomes from a randomized controlled trialhttps://www.pharmaradar360.com/article/clinical-and-metabolic-links-between-hypothyroidism-and-metabolic-syndrome-a-rev-26b2ca25872be00bPharmaRadar360en2026-09-18T00:00:00.000ZClinical and metabolic links between hypothyroidism and metabolic syndrome: a reviewhttps://www.pharmaradar360.com/article/non-guideline-compliant-prescriptions-of-benzodiazepines-and-z-drugs-effects-of-c82e1f698d7a330bPharmaRadar360en2026-09-18T00:00:00.000ZNon-guideline—compliant prescriptions of benzodiazepines and Z drugs: Effects of social norm feedback. A randomized controlled trialhttps://www.pharmaradar360.com/article/prevalence-and-early-predictors-of-metabolic-syndrome-among-adolescents-0979e56242690ce4PharmaRadar360en2026-09-18T00:00:00.000ZPrevalence and early predictors of Metabolic Syndrome Among Adolescentshttps://www.pharmaradar360.com/article/a-rare-case-report-of-lateral-periodontal-cyst-86813d462bd1795cPharmaRadar360en2026-09-18T00:00:00.000ZA rare case report of Lateral Periodontal Cysthttps://www.pharmaradar360.com/article/soluble-urokinase-type-plasminogen-activator-receptor-in-glomerular-disease-a-ma-e62ed0c5b157c549PharmaRadar360en2026-09-18T00:00:00.000ZSoluble urokinase-type plasminogen activator receptor in glomerular disease: a marker of activity or renal vulnerability?https://www.pharmaradar360.com/article/high-flow-nasal-cannula-in-adult-acute-care-physiological-mechanisms-clinical-ev-8f7e270a8cc693dcPharmaRadar360en2026-09-18T00:00:00.000ZHigh-Flow Nasal Cannula in Adult Acute Care: Physiological Mechanisms, Clinical Evidence, and Persistent Misconceptionshttps://www.pharmaradar360.com/article/oxford-nanopore-based-genomic-characterization-of-macrolide-resistance-in-clinic-b0635c7940c6e532PharmaRadar360en2026-09-18T00:00:00.000ZOxford Nanopore-Based Genomic Characterization of Macrolide Resistance in Clinical &lt;em&gt;Streptococcus pyogenes&lt;/em&gt; Isolateshttps://www.pharmaradar360.com/article/nucleic-acids-in-medicinal-plants-and-their-pharmaceutical-potential-5a69fb06fb585d6aPharmaRadar360en2026-09-18T00:00:00.000ZNucleic acids in medicinal plants and their pharmaceutical potentialhttps://www.pharmaradar360.com/article/diagnostic-value-of-urinary-albumin-creatinine-ratio-in-predicting-vision-threat-11c3ec9b9f2d15fcPharmaRadar360en2026-09-18T00:00:00.000ZDiagnostic value of urinary albumin creatinine ratio in predicting vision-threatening diabetic retinopathy in patients with diabetes: a systematic review and Meta-analysishttps://www.pharmaradar360.com/article/visual-and-accommodative-outcomes-after-femtosecond-lasik-with-and-without-monov-8f815f409c403df3PharmaRadar360en2026-09-18T00:00:00.000ZVisual and accommodative outcomes after femtosecond LASIK with and without monovision in patients over 40 yearshttps://www.pharmaradar360.com/article/effect-of-manual-diaphragmatic-release-technique-on-exercise-capacity-and-sleep-a526395573a1476fPharmaRadar360en2026-09-18T00:00:00.000ZEffect of manual diaphragmatic release technique on exercise capacity and sleep quality in older adults with Type II diabetes: A randomized controlled trialhttps://www.pharmaradar360.com/article/collaborative-clinical-research-ethics-and-regulatory-governance-in-sub-saharan-a80d218f6a293c6dPharmaRadar360en2026-09-18T00:00:00.000ZCollaborative clinical research ethics and regulatory governance in Sub-Saharan Africa: Gaps, challenges and implicationshttps://www.pharmaradar360.com/article/saikosaponin-d-ameliorates-non-alcoholic-steatohepatitis-by-inhibiting-sting-med-d926f3f53f604836PharmaRadar360en2026-09-18T00:00:00.000ZSaikosaponin D Ameliorates Non-alcoholic Steatohepatitis by Inhibiting STING-Mediated Macrophage M1 Polarization in Micehttps://www.pharmaradar360.com/article/pubertal-delay-in-patients-with-paternally-derived-15q11-2-q13-duplication-syndr-97e9e561d7acd17bPharmaRadar360en2026-09-18T00:00:00.000ZPubertal delay in patients with paternally derived 15q11.2–q13 duplication syndrome and <i>MKRN3</i> overexpressionhttps://www.pharmaradar360.com/article/degradation-of-pharmaceutical-pollutants-in-wastewater-via-cellulose-microsphere-8720e55e1d533a4bPharmaRadar360en2026-09-18T00:00:00.000ZDegradation of Pharmaceutical Pollutants in Wastewater via Cellulose Microspherehttps://www.pharmaradar360.com/article/ai-driven-wearable-gadgets-for-personalization-of-drug-therapy-in-human-and-vete-ad56ba1a0ef26dd0PharmaRadar360en2026-09-18T00:00:00.000ZAI-Driven Wearable Gadgets for Personalization of Drug Therapy in Human and Veterinary Medicinehttps://www.pharmaradar360.com/article/leveraging-community-health-workers-for-the-promotion-of-breast-cancer-awareness-755600d79ec1f2d3PharmaRadar360en2026-09-18T00:00:00.000ZLeveraging community health workers for the promotion of Breast Cancer Awareness and Timely Help-Seeking Behaviour (BreCATH-B study), among underserved rural population in Kenya: a protocol for a hybrid type II cluster randomised controlled trialhttps://www.pharmaradar360.com/article/development-of-a-telerehabilitation-based-exercise-and-monitoring-program-and-it-be132e0c48930f0aPharmaRadar360en2026-09-18T00:00:00.000ZDevelopment of a telerehabilitation-based exercise and monitoring program and its effectiveness compared with a brochure-based home exercise program in patients with lumbar disc herniation: a randomized controlled trialhttps://www.pharmaradar360.com/article/correction-novel-covalent-cdk7-inhibitor-potently-induces-apoptosis-in-acute-mye-92e394580899b083PharmaRadar360en2026-09-18T00:00:00.000ZCorrection: Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclaxhttps://www.pharmaradar360.com/article/differentiable-latent-structure-discovery-for-interpretable-forecasting-in-clini-0cd199136d6e8b1fPharmaRadar360en2026-09-18T00:00:00.000ZDifferentiable latent structure discovery for interpretable forecasting in clinical time serieshttps://www.pharmaradar360.com/article/practice-variation-in-hospital-care-for-pelvic-organ-prolapse-and-urinary-incont-3d823e631c47eefePharmaRadar360en2026-09-18T00:00:00.000ZPractice variation in hospital care for pelvic organ prolapse and urinary incontinence: an analysis of specialists’ expectations, cross-sectional claims data, and the role of clinical guidelineshttps://www.pharmaradar360.com/article/clinical-and-financial-correlates-of-suicide-attempts-among-patients-with-gambli-02d0125d246d53edPharmaRadar360en2026-09-18T00:00:00.000ZClinical and financial correlates of suicide attempts among patients with gambling disorder: a retrospective studyhttps://www.pharmaradar360.com/article/clinical-characteristics-of-childhood-systemic-lupus-erythematosus-complicated-b-7f3038027461f1c3PharmaRadar360en2026-09-18T00:00:00.000ZClinical characteristics of childhood systemic lupus erythematosus complicated by cerebral venous sinus thrombosis: a case report and literature reviewshttps://www.pharmaradar360.com/article/randomized-phase-iii-trial-with-a-factorial-design-assessing-the-efficacy-and-sa-7ec071caeffd2817PharmaRadar360en2026-09-18T00:00:00.000ZRandomized phase III trial with a factorial design assessing the efficacy and safety of darolutamide and stereotactic dose-escalated radiotherapy in patients with high-risk localized prostate cancer: the PEACE 7 (GETUG-AFU 45) study protocolhttps://www.pharmaradar360.com/article/drug-induced-phospholipidosis-following-haematopoietic-stem-cell-transplantation-ab9302e7e11d6b1dPharmaRadar360en2026-09-18T00:00:00.000ZDrug induced phospholipidosis following haematopoietic stem cell transplantation complicated by graft versus host disease: a small case serieshttps://www.pharmaradar360.com/article/clinical-outcomes-of-combined-hepatic-arterial-infusion-chemotherapy-with-target-ff41a7de4710bf07PharmaRadar360en2026-09-18T00:00:00.000ZClinical outcomes of combined hepatic arterial infusion chemotherapy with targeted or immunotherapy in advanced hepatocellular carcinomahttps://www.pharmaradar360.com/article/ludwig-s-angina-in-somalia-clinical-characteristics-emergency-management-and-out-db48f21f0e692542PharmaRadar360en2026-09-18T00:00:00.000ZLudwig’s angina in Somalia: clinical characteristics, emergency management, and outcomes from a tertiary academic referral centerhttps://www.pharmaradar360.com/article/powered-by-curiosity-the-emerge-model-for-advancing-clinical-research-leadership-97ddb4d925def0acPharmaRadar360en2026-09-18T00:00:00.000ZPowered by curiosity: the EMERGE model for advancing clinical research leadershiphttps://www.pharmaradar360.com/article/long-term-survivorship-of-transfibular-trabecular-metal-total-ankle-arthroplasty-045567ef15fb6238PharmaRadar360en2026-09-18T00:00:00.000ZLong-term Survivorship of Transfibular Trabecular Metal Total Ankle Arthroplasty: 10-Year Minimum Clinical and Radiographic Follow-uphttps://www.pharmaradar360.com/article/short-term-effects-of-radial-extracorporeal-shock-wave-therapy-in-addition-to-ph-7f21e74b24247cd4PharmaRadar360en2026-09-18T00:00:00.000ZShort-Term Effects of Radial Extracorporeal Shock Wave Therapy in Addition to Physiotherapy on Spasticity, Walking Performance, and Quality of Life in Chronic Stroke: A Sham-Controlled Randomized Trialhttps://www.pharmaradar360.com/article/ensuring-x-ray-safety-in-merowe-sudan-78999d828fcc67c9PharmaRadar360en2026-09-18T00:00:00.000ZEnsuring X-ray Safety in Merowe, Sudanhttps://www.pharmaradar360.com/article/nomenclature-standardization-and-health-care-technology-management-0fd3438ec1bfdb35PharmaRadar360en2026-09-18T00:00:00.000ZNomenclature Standardization and Health Care Technology Managementhttps://www.pharmaradar360.com/article/peri-plate-gas-detected-on-cervical-ct-as-an-exploratory-imaging-indicator-of-es-d84e1111a3a9cba7PharmaRadar360en2026-09-18T00:00:00.000ZPeri-Plate Gas Detected on Cervical CT as an Exploratory Imaging Indicator of Esophageal Perforation After Anterior Cervical Spine Surgeryhttps://www.pharmaradar360.com/article/general-dermatology-and-dermatology-in-primary-health-care-3ec6d2b585374c21PharmaRadar360en2026-09-18T00:00:00.000ZGeneral Dermatology and Dermatology in Primary Health Carehttps://www.pharmaradar360.com/article/comment-on-acneiform-eruption-with-deucravacitinib-systematic-review-and-meta-an-8a8d04909efec9c9PharmaRadar360en2026-09-18T00:00:00.000ZComment on ‘Acneiform Eruption with Deucravacitinib: Systematic Review and Meta-Analysis’https://www.pharmaradar360.com/article/determinants-of-community-pharmacists-intention-to-provide-pharmacist-driven-vac-e1abbf554c80558cPharmaRadar360en2026-09-18T00:00:00.000ZDeterminants of community pharmacists’ intention to provide pharmacist-driven vaccination services in selected Arabic-speaking countries: a theory of planned behaviour-based structural equation modelling studyhttps://www.pharmaradar360.com/article/ecologically-inspired-green-walls-addressing-structural-and-biological-barriers-6db5246f66fa54fbPharmaRadar360en2026-09-18T00:00:00.000ZEcologically inspired green walls: addressing structural and biological barriers through novel substrate design – an experimental trialhttps://www.pharmaradar360.com/article/prevalence-and-associated-factors-of-cognitive-impairment-in-patients-with-major-9ec172616c914ae2PharmaRadar360en2026-09-18T00:00:00.000ZPrevalence and associated factors of cognitive impairment in patients with major depressive disorder: a cross-sectional study in Vietnamhttps://www.pharmaradar360.com/article/recognizing-paediatric-ocular-rosacea-clinical-spectrum-diagnostic-clues-and-tre-aa7a7e67addf65f1PharmaRadar360en2026-09-18T00:00:00.000ZRecognizing Paediatric Ocular Rosacea: Clinical Spectrum, Diagnostic Clues, and Treatment Outcomeshttps://www.pharmaradar360.com/article/effect-of-transcutaneous-auricular-vagus-nerve-stimulation-on-postoperative-gast-b4866bdcf6032b2fPharmaRadar360en2026-09-18T00:00:00.000ZEffect of transcutaneous auricular vagus nerve stimulation on postoperative gastrointestinal dysfunction in patients with gynecological abdominal or pelvic tumors: a study protocol for a prospective, single-center, randomized, controlled clinical trial